Organisation paid for research Program year 2025 Source: CMS Open Payments

Dz1lfo Multi Global Conglomerate Inc

Neither a doctor nor a teaching hospital

Research payments

$986,611

272 payments

Through program year 2025, Dz1lfo Multi Global Conglomerate Inc is reported as receiving $986,611 in research payments, across 272 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $269,331 110
2024 Research $161,397 43
2023 Research $259,668 62
2022 Research $228,672 40
2021 Research $67,543 17

Breakdown

Who paid Research payments · program years 2021–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $658,145 163 payments
  2. F. Hoffmann-La Roche AG $100,141 30 payments
  3. Arena Pharmaceuticals, Inc. $85,968 28 payments
  4. Genentech, Inc. $85,374 39 payments
  5. AbbVie, Inc. $40,078 6 payments
  6. Pfizer Inc. $16,905 6 payments
Studies the money was for Research payments · program years 2021–2025
  1. Phase 3, Multicenter, Randomized Study With 2 Different Doses of Prucalopride Administered to Male and Female Pediatric Subjects Aged 6 Months to 17 Years With Functional Constipation, Consisting of A 12-Week Double-Blind, Placebo-Controlled Part (Part A) to Evaluate Efficacy and Safety Followed By A 36-Week Double-Blind Extension Part (Part B) to Document Long-Term Safety Up to Week 48 $499,180 100 payments
  2. UC P3: Double-Blind Treat Straight Through $185,515 69 payments
  3. A Phase 2 Randomized Doubleblind Placebocontrolled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis $102,873 34 payments
  4. A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis $72,089 27 payments
  5. A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects $57,783 20 payments
  6. TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis $29,092 16 payments
  7. Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $16,915 2 payments
  8. Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $8,879 1 payment
  9. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $8,247 1 payment
  10. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $6,037 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record